Advanced Accelerator Applications

Last updated
Advanced Accelerator Applications
Industry Pharmaceuticals
Founded2002 (2002)
Headquarters Saint-Genis-Pouilly, France
Key people
 Sidonie Golombowski-Daffner, Chairperson and President
ProductsGluscan, Dopaview, Fluorochol/Aaacholine, Netspot, Somakit Toc
Number of employees
>1000
Parent Novartis
Website adacap.com

Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases. [2]

Contents

In late October 2017, Reuters announced that Novartis would acquire the company for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium. [3] On January 22, 2018, Novartis AG announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A. [4]

History

AAA was created in 2002 by Italian physicist Stefano Buono to exploit a patent from the European Organization for Nuclear Research (CERN). [5]

AAA currently has a total of 31 sites in 12 countries, including: 19 production facilities in 8 countries (in Europe and the U.S.) that manufacture targeted radioligand therapies and precision imaging radioligands, and 6 sites with R&D activity.

In October 2017, Novartis announced that it intended to acquire the company for US$3.9 billion. [6]

Products

AAA has a portfolio of diagnostic and therapeutic applications and products in the fields of Molecular Imaging and Therapy. [7] The group's portfolio of radiopharmaceuticals includes radioactive agents for positron emission tomography (PET) imaging as well as single-photon emission computed tomography (SPECT) diagnostic products. [8]

Lutathera

The company's lead product is LUTATHERA, a Lutetium Lu 177 dotatate labeled somatostatin analogue peptide, [9] a theragnostic cancer product being developed to treat certain gastro-entero pancreatic neuroendocrine tumors (GEP-NETs). [10] It selectively targets over-expressed somatostatin receptors while also giving off gamma emissions to allow physicians to visualize where in the body both the drug and the tumor are. It was approved by the FDA in January 2018 for GEP-NET. [11]

Approval

Lutathera, also known as lutetium Lu 177 dotatate, is a target treatment drug for patients with GEP-NETs. [12] Its approval for Advanced Accelerator Applications was announced on January 26, 2018, by the US Food and Drug Administration. [13] Lutathera is most notable as the first FDA approved peptide receptor radionuclide therapy (PRRT) to combat GEP-NETs. [14]

GEP-NETs

GEP-NETs are rare groups of cancer that continue to proliferate, regardless of initial therapy treatments. [12] They are present in areas affected by pancreatic or gastrointestinal cancers; specifically, the pancreas, stomach, intestines, colon and rectum. [13]

Use

Lutathera is used to combat pancreatic and gastrointestinal cancers that do not respond well to common chemotherapeutical treatments; namely for patients with somatostatin receptor-positive GEP-NETs. [12] [13] These receptors are commonly found on tumors located in the foregut, midgut, and hindgut. [15]

Mechanism

Lutathera is a radioactive drug consisting of a tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) attached to the chelating agent tetraazacyclododecanetetra-acetic acid (DOTA). [16] Attached to the dotatate is the radioactive marker Lu-177, a radioisotope. [12] The dotatate binds to the GEP-NET positive somatostatin receptor cells commonly present on neuroendocrine tumors. [12] [16] After binding to the receptor, Lutathera enters the cell and uses its radioactive property to damage DNA. [12] This mechanism effectively triggers apoptosis of cancerous tumor cells. As a result, studies found that 16% of patients being treated with Lutathera experienced either complete or partial tumor shrinkage. [12]

Studies

FDA approval of Lutathera was ultimately supported by two clinical studies. [13] NETTER-1, a Phase 3 study, was a randomized clinical trial which included patients with a severe form of somatostatin receptor-positive NETs. [12] [14] The study compared Lutathera treatment with a standard dose of octreotided LAR against a high-dose of octreotide LAR. [12] Researchers measured tumor growth after the course of the treatment, also known as progression-free survival. [13] The study concluded that patients who were treated with Lutathera lived substantially longer compared to those who only received the octreotide treatment. [12] They experienced a 79% reduction in death and cancer progression. [14]

The Netherlands study gathered several patients with somatostatin receptor-positive tumors, including patients with GEP-NETs. [12] The study found that 16% of patients with GEP-NETs, who were treated with Lutathera, experienced complete or partial tumor shrinkage. [12] As a result, a pre-planned interim overall survival analysis found that Lutathera treatment lead to a 48% reduction in risk of death. [14]

Common Grade 3-4 Adverse Reactions

Common problemsSymptoms/ReactionsPercent of patients affected
Nausea5%
Vomiting7%
Hyperglycemia4%
Hypokalemia4%
Liver problems
Increased Gamma-Glutamyl Transferase20%
Elevated AST5%
Increased ALT4%
Tumor bleeding
Swelling (edema)
Tissue injury (necrosis)
Bone Marrow problems
Myelodysplastic syndrome2%
Acute leukemia1%
Kidney problems
Kidney failure2%
Neuroendocrine hormonal crisis
Hypotension1%
Bronchospasm
Myelosuppression1%
Lymphopenia44%
Anemia
Thrombocytopenia
Leukopenia
Neutropenia
Cardiac problems
Myocardial infarction1%
Cardiac failure2%
Embryo-Fetal Toxicity
Causes harm to unborn fetuses
Temporary Infertility
May cause infertility

[12] [13] [14] [15]

Advances

Lutathera is a major technological advancement for the detection of tumors. Diagnostic imaging that relies on dotatates can now rely on Lutathera to locate somatostatin receptor-positive tumors by tagging them with its radioactive component. [12] This tagging of tumors will allow them to become more visible during positron emission tomography (PET) scans. [12] With LU-177 dotatates, more somatostatin receptor-positive GEP-NET patients can be identified for treatment of the disease. [12]

Pipeline

AAA has a broad pipeline of products in development, including several theragnostic pairings for oncology indications.

NETSPOT and SomaKit TOC are novel kits for radiolabeling somatostatin analogue peptides to help diagnose somatostatin receptor-positive NET lesions. Each kit has received orphan drug designation from both the EMA and the FDA. [17] [18]

99MTc-rhAnnexin V-128, a SPECT investigational candidate for the diagnosis and assessment of apoptotic and necrotic processes, which are present in a number of pathological conditions in oncology and cardiovascular disease, as well as in autoimmune disorders. 99MTc-rhAnnexin V-128 is currently in a Phase I/II trial for the diagnosis of rheumatoid arthritis and ankylosing spondylitis, as well as several Phase II studies in cardiovascular, cardio-oncology, and pulmonary indications.

177Lu-PSMA-617 and 68Ga-PSMA-617 are in development to treat, image, monitor and stage prostate cancer. PSMA-617 is a ligand of prostate-specific membrane antigen (PSMA) expressed on the majority of prostate tumor cells. 177Lu-PSMA-617 also known as lutetium (177Lu) vipivotide tetraxetan is being developed to treat prostate cancer by binding to PSMA-617. In June 2021 it was granted a breakthrough therapy designation. [19] 68Ga-PSMA-617 is under development as a complementary diagnostic candidate.

CTT1057 is an 18F-labeled investigational diagnostic candidate in development for PET imaging of prostate cancer. CTT1057 is a phosphoramidate-based peptide, which specifically binds to Prostate-Specific Membrane Antigen (PSMA), expressed on the majority of prostate tumor cells.

177LuNeoBOMB1 and 68GaNeoBOMB1 are new generation antagonist bombesin analogs in development to treat, image, monitor and stage gastrin-releasing peptide receptor (GRPR)-expressing malignancies, such as such as gastrointestinal stromal tumors (GIST), prostate cancer and breast cancer. 177LuNeoBOMB1 is a therapeutic candidate and 68GaNeoBOMB1 is its complementary diagnostic candidate.

Millburn site

In 2016, AAA opened a light manufacturing and distribution site in Millburn, NJ, a residential town in North Jersey. [20] When the site was first purchased, it caused substantial concerns among local residents. [21] Per the requests of Millburn Residents, the Township Committee hired a nuclear/radiology expert to re-assess the appropriateness of opening a radioactive manufacturing site in the residential area. [22] The expert concluded that the proposed operations at AAA are safe and pose no hazard to the citizens of Millburn. [23] [24]

Related Research Articles

3-Aminopyridine-2-carboxaldehyde thiosemicarbazone Chemical compound

3-Aminopyridine-2-carboxaldehyde thiosemicarbazone is a substance that is being studied in the treatment of cancer.

Carcinoid syndrome Medical condition

Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary to carcinoid tumors. The syndrome includes flushing and diarrhea, and less frequently, heart failure, vomiting and bronchoconstriction. It is caused by endogenous secretion of mainly serotonin and kallikrein.

A gallium scan is a type of nuclear medicine test that uses either a gallium-67 (67Ga) or gallium-68 (68Ga) radiopharmaceutical to obtain images of a specific type of tissue, or disease state of tissue. Gallium salts like gallium citrate and gallium nitrate may be used. The form of salt is not important, since it is the freely dissolved gallium ion Ga3+ which is active. Both 67Ga and 68Ga salts have similar uptake mechanisms. Gallium can also be used in other forms, for example 68Ga-PSMA is used for cancer imaging. The gamma emission of gallium-67 is imaged by a gamma camera, while the positron emission of gallium-68 is imaged by positron emission tomography (PET).

Neuroendocrine tumor Medical condition

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung, and the rest of the body.

Lanreotide

Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2.

Glutamate carboxypeptidase II

Glutamate carboxypeptidase II (GCPII), also known as N-acetyl-L-aspartyl-L-glutamate peptidase I, NAAG peptidase, or prostate-specific membrane antigen (PSMA) is an enzyme that in humans is encoded by the FOLH1 gene. Human GCPII contains 750 amino acids and weighs approximately 84 kDa.

Copper-64 (64Cu) is a positron and beta emitting isotope of copper, with applications for molecular radiotherapy and positron emission tomography. Its unusually long half-life (12.7-hours) for a positron-emitting isotope makes it increasingly useful when attached to various ligands, for PET and PET-CT scanning.

Indium-111 (111In) is a radioactive isotope of indium (In). It decays by electron capture to stable cadmium-111 with a half-life of 2.8 days. Indium-111 chloride (111InCl) solution is produced by proton irradiation of a cadmium target in a cyclotron, as recommended by International Atomic Energy Agency (IAEA). The former method is more commonly used as it results in a high level of radionuclide purity.

DOTA-TATE Eight amino-acid long peptide covalently bonded to a DOTA chelator

DOTA-TATE is an eight amino acid long peptide, with a covalently bonded DOTA bifunctional chelator.

Edotreotide Chemical compound

Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. When used therapeutically it is an example of peptide receptor radionuclide therapy.

Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis.

Ribociclib

Ribociclib, sold under the brand name Kisqali and Kryxana marketed by Novartis, is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor indicated in combination with: an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; or fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals. Ribociclib is currently the only CDK4/6 inhibitor with a proven benefit on overall survival across all three Phase III trials of the MONALEESA clinical program with different endocrine therapy partners, regardless of menopausal status or line of therapy. The European Society of Medical Oncology (ESMO) assigned the highest score on the 'Magnitude of Clinical Benefit Scale' for Kisqali.

Siroos Mirzaei Iranian specialist in Nuclear Medicine (born 1963)

Siroos Mirzaei is an Iranian specialist in Nuclear Medicine. He is Head of the Department of Nuclear Medicine of the Wilhelminen Hospital in Vienna. Mirzaei is well known for his scientific work on torture diagnostics with molecular imaging methods.

Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre. He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.

Matthew Kulke is an American cancer researcher. He is the Chief of Hematology/Oncology, co-director of the BU/BMC Cancer Center and "Zoltan Kohn Professor" at the Boston University School of Medicine. His work has shed light on the molecular characteristics of neuroendocrine tumors and has led to the development of multiple new treatments for this condition. His research studies led to the development and approval of telotristat ethyl, a tryptophan hydroxylase inhibitor, for the treatment of patients with carcinoid syndrome. He has also contributed to early and late stage clinical trials of temozolomide, sunitinib, everolimus, and peptide receptor radiotherapy for neuroendocrine tumors.

Peptide receptor radionuclide therapy Type of radiotherapy

Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets peptide receptors to deliver localised treatment, typically for neuroendocrine tumours (NETs).

Lutetium (<sup>177</sup>Lu) oxodotreotide Chelate of Lu-177 with DOTA-TATE, a peptide derivative bound to a DOTA molecule

Lutetium (177Lu) oxodotreotide (INN) or 177Lu DOTA-TATE, trade name Lutathera, is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). Specifically, it is used in the treatment of cancers which express somatostatin receptors.

Copper (<sup>64</sup>Cu) oxodotreotide Radioactive diagnostic agent used in PET scan to localize tumors

Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults.

Piflufolastat F-18

Piflufolastat F-18, sold under the brand name Pylarify, is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. It is given by intravenous injection.

Lutetium (<sup>177</sup>Lu) vipivotide tetraxetan

Lutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Lutetium (177Lu) vipivotide tetraxetan is a targeted radioligand therapy.

References

  1. ↑ PrivateEquityWire, "Advanced Accelerator Applications completes fundraising", Feb 18th, 2014
  2. ↑ Il Sole 24 Ore, "Dal Cern and Biopark canavese", March 12th, 2014
  3. ↑ Miller, John (3 November 2017). "Novartis to buy French cancer specialist AAA for $3.9 billion". Reuters.
  4. ↑ "Novartis Completes Tender Offer for Advanced Accelerator Applications" (Press release). Novartis. 23 January 2018.
  5. ↑ AdnKronos," Research: from Rubbia to AAA, great success for an Italian physicist with European company". March 19th, 2010.
  6. ↑ Wirtschaftswoche. "Advanced Accelerator Applications: Novartis kauft Krebsspezialisten für 3,9 Milliarden Dollar". www.wiwo.de (in German). Retrieved 2022-08-20.
  7. ↑ "Advanced Accelerator Applications Nuclear Medicine Glossary". Archived from the original on 2015-04-13. Retrieved 2015-04-15.
  8. ↑ "Medicaldevicedaily.com, "AAA to increase clinical trials of MNM diagnostic products", Febr 19th, 2014" (PDF). Archived from the original (PDF) on 2014-04-08. Retrieved 2014-04-07.
  9. ↑ Larsen, Peter Thal (30 October 2017). "Novartis Makes a Deal That Should Go Down Easy". The New York Times.
  10. ↑ Warner, Jeremy L; Fitts, Austin; Warner, Jeremy (6 May 2021). "Lutetium Lu 177 dotatate (Lutathera)". HemOnc.org. Retrieved 14 August 2022.
  11. ↑ FDA approves Lutathera for gastroenteropancreatic neuroendocrine tumors Jan 2018
  12. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 "FDA Approves New Treatment for Neuroendocrine Tumors". National Cancer Institute. 8 February 2018. Retrieved 2018-05-26.
  13. 1 2 3 4 5 6 Commissioner, Office of the. "Press Announcements - FDA approves new treatment for certain digestive tract cancers". www.fda.gov. Retrieved 2018-05-26.
  14. 1 2 3 4 5 "Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors | Novartis". Novartis. Retrieved 2018-05-26.
  15. 1 2 "For Patients - Lutathera". Lutathera. Retrieved 2018-05-26.
  16. 1 2 "NCI Drug Dictionary". National Cancer Institute. Retrieved 2018-05-26.
  17. ↑ Devicespace.com, "Advanced Accelerator Applications Receives Orphan Drug Designation From FDA And European Medicines Agency For Gallium-68 DOTATATE For Use In Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors" Archived 2014-04-08 at the Wayback Machine . 3 March 2014.
  18. ↑ News Medical, "AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE". 4 March 2014.
  19. ↑ Parsons, Lucy (2021-06-21). "Novartis' radioligand therapy granted US Breakthrough Therapy Designation". PharmaTimes Online. Retrieved 2021-07-10.
  20. ↑ Danielle Desisto. "Millburn manufacturing site safely produces cancer-fighting drug".
  21. ↑ "Concerns raised about proposed cancer drug factory in Millburn"
  22. ↑ Cecilia Levine. "Nuclear meds expert hired". The Record. 7 May 2015.
  23. ↑ Jonathan Sym. "Advanced Accelerator Application Investigation Results: Risks Are "Close To Zero Without Being Zero" Says Expert". Tap Into Millburn/Short Hills. 18 February 2016.
  24. ↑ Harry Trumbore. "Expert says radiopharmaceutical factory proposed for Millburn is safe" . 11 February 2016
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.